Published in Toxicol Appl Pharmacol on September 15, 1989
Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest (2000) 2.26
Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest (1995) 1.52
Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis. Am J Pathol (2010) 0.95
Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2013) 0.92
Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo. PLoS One (2012) 0.84
Dose-response Effects of Bleomycin on Inflammation and Pulmonary Fibrosis in Mice. Toxicol Res (2010) 0.82
Identification of P-Rex1 as an anti-inflammatory and anti-fibrogenic target for pulmonary fibrosis. Sci Rep (2016) 0.77
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med (1985) 2.92
Preparation of lymphocyte-activating factor from continuous murine macrophage cell lines. Cell Immunol (1977) 2.81
Partial purification of human lymphocyte-activating factor (LAF) by ultrafiltration and electrophoretic techniques. J Immunol (1977) 2.58
Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J Immunol (1991) 2.52
Overexpression of metallothionein confers resistance to anticancer drugs. Science (1988) 2.03
Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol (1989) 1.40
Suppression of murine collagen-induced arthritis with monoclonal anti-Ia antibodies and augmentation with IFN-gamma. J Immunol (1988) 1.26
The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction. J Immunol (1988) 1.20
Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J Leukoc Biol (1993) 1.15
1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. Bioorg Med Chem Lett (2000) 1.14
Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol (1995) 1.12
Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res (1999) 1.12
T cell development in normal and thymopentin-treated nude mice. J Exp Med (1982) 1.06
Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones. J Med Chem (1991) 1.06
B16 murine melanoma and aging: slower growth and longer survival in old mice. J Natl Cancer Inst (1984) 0.97
Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. Science (1985) 0.95
Effect of cytotoxic monoclonal antibody depletion of T-lymphocyte subpopulations on bleomycin-induced lung damage in C57BL/6J mice. Toxicol Appl Pharmacol (1989) 0.92
Mechanisms of asbestos-induced nitric oxide production by rat alveolar macrophages in inhalation and in vitro models. Free Radic Biol Med (1998) 0.92
Genomic cloning and heterologous expression of human differentiation-stimulating factor. DNA (1989) 0.91
Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. Cancer Lett (1995) 0.91
Specific in vivo and in vitro antibody response to tetanus toxoid immunization. Clin Exp Immunol (1982) 0.90
Genetic control of tolerance induction to human gamma-globulin in mice. J Immunol (1978) 0.88
In vivo immunomodulation by monoclonal anti-L3T4. 1. Effects on humoral and cell-mediated immune response. Cell Immunol (1987) 0.88
Nitric oxide modulates lymphocyte proliferation but not secretion of IL-2. Immunol Invest (1993) 0.88
Serotonin-activated signal transduction via serotonin receptors on Jurkat cells. J Immunol (1990) 0.87
Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol (1995) 0.87
Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J Med Chem (1990) 0.86
Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles. Cancer Res (1986) 0.85
Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem Pharmacol (1993) 0.84
Discovery of a new class of p38 kinase inhibitors. Bioorg Med Chem Lett (2000) 0.83
Inhibition of ceramide pathway does not affect ability of TNF-alpha to activate nuclear factor-kappa B. J Immunol (1994) 0.83
Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice. Cancer Res (1982) 0.82
Cimetidine and the immune response. I. In vivo augmentation of nonspecific and specific immune response. Clin Immunol Immunopathol (1983) 0.82
Drug resistance results in alterations in expression of immune recognition molecules and failure to express Fas (CD95). Immunol Cell Biol (1998) 0.82
Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs. Cancer Res (1985) 0.81
Anti-tumor necrosis factor receptor and tumor necrosis factor agonist activity by an anti-idiotypic antibody. Eur J Immunol (1992) 0.80
Effect of osmotic diuresis on gentamicin-induced nephrotoxicity in rats. Arch Toxicol (1980) 0.80
Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro. Cancer Lett (1986) 0.80
Correlation of altered tyrosine phosphorylation with methotrexate resistance in a cisplatin-resistant subline of L1210 cells. Biochem Pharmacol (1996) 0.79
Effect of erythrocytes on alveolar macrophage cytostatic activity induced by bleomycin lung damage in rats. Cancer Res (1990) 0.79
Aza and diaza bioisosteric anthracene-9,10-diones as antitumor agents. Acta Biochim Pol (1995) 0.79
Investigations on the mechanisms of methotrexate resistance in a cisplatin-resistant L1210 murine leukemia cell subline. Cancer Chemother Pharmacol (1996) 0.79
Impact of the basic amine on the biological activity and intracellular distribution of an aza-anthrapyrazole: BBR 3422. Biochem Pharmacol (2001) 0.78
Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine. Cancer Res (1981) 0.78
Suppression of T cell cytotoxicity by nude mouse spleen cells: reversal by monosaccharides and interleukin 2. J Immunol (1983) 0.78
Collateral methotrexate resistance in cisplatin-selected murine leukemia cells. Braz J Med Biol Res (1999) 0.78
Specific antibody synthesis in vitro. II. Age-associated thymosin enhancement of antitetanus antibody synthesis. Immunopharmacology (1984) 0.78
6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J Med Chem (1994) 0.77
Specific antibody synthesis in vitro. I. Technical considerations. J Immunol Methods (1984) 0.77
Experimental tumors and aging: local factors that may account for the observed age advantage in the B16 murine melanoma model. Exp Gerontol (1984) 0.77
Synthesis and antineoplastic evaluations of 5,8-bis[(aminoalkyl)amino]-1-azaanthracene-9,10-diones. J Med Chem (1985) 0.77
Development of T-cell function in relation to T-cell set diversification in nu/nu mice. Cell Immunol (1986) 0.77
Assessment of bleomycin-, tallysomycin-, and polyamine-mediated acute lung toxicity by pulmonary lavage angiotensin-converting enzyme activity. Toxicol Appl Pharmacol (1981) 0.77
Immunotherapy of autoimmune disease with T cell subset specific antibodies. Concepts Immunopathol (1987) 0.77
Increased oxidant resistance of alveolar macrophages isolated from rats repeatedly exposed to cadmium aerosols. Toxicology (1996) 0.76
Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles). J Med Chem (1998) 0.76
Synthesis and antitumor activities of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and related systems. J Med Chem (1986) 0.76
Modulation of methotrexate resistance by genistein in murine leukemia L1210 cells. Oncol Rep (1998) 0.76
A synthetic mycobacterial heat shock peptide prevents adjuvant arthritis but not proteoglycan-induced synovitis in the rat. Agents Actions (1991) 0.76
Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (R,R-1,2-diaminocyclohexane) bis(shikimato) platinum(II). Evidence for a novel rearrangement involving platinum-carbon bond formation. J Inorg Biochem (1991) 0.76
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas. Bioorg Med Chem Lett (2001) 0.75
Role of reactive nitrogen intermediate production in alveolar macrophage-mediated cytostatic activity induced by bleomycin lung damage in rats. Cancer Res (1990) 0.75
Effect of disulfiram on cyclophosphamide toxicity: a clinical trial. Cancer Treat Rep (1983) 0.75
Adriamycin-mediated inhibition of creatine phosphokinase binding to heart mitochondrial membrane. Biochem Pharmacol (1982) 0.75
Tumor vasculature in young and old hosts: scanning electron microscopy of microcorrosion casts with microangiography, light microscopy and transmission electron microscopy. Scanning Microsc (1987) 0.75
Chronobiologic fluctuation of cyclophosphamide induced urinary bladder damage in mice. Chronobiologia (1984) 0.75
Synthesis and antitumor activities of 5-methyl-1- and 2-[[2-dimethylaminoethyl]amino]-aza-thiopyranoindazoles. Bioorg Med Chem Lett (2000) 0.75
Organ-directed toxicology of antitumor agents. Symposium summary. Fed Proc (1985) 0.75
VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor. Biochem Biophys Res Commun (2000) 0.75
Heterosubstituted anthracene-9,10-dione analogues. The synthesis and antitumor evaluation of 5,8-bis[(aminoalkyl)amino]naphtho[2,3-b] thiophene-4,9-diones. J Med Chem (1990) 0.75
Prevention of cyclophosphamide-induced haemorrhagic cystitis by disulfiram. Blut (1982) 0.75
Anticholinesterase activity of the unsymmetric bisquaternary 6-aminoquinoline salt NSC-176319. Biochem Pharmacol (1982) 0.75
Pharmacologic and toxicologic evaluation of thioproline: a proposed nontoxic inducer of reverse transformation. Cancer Treat Rep (1981) 0.75
The effect of L-3, 4-dehydroproline on the antitumor activity and toxicity of bleomycin. Toxicol Appl Pharmacol (1983) 0.75
Formation of nitric oxide hemoglobin in erythrocytes co-cultured with alveolar macrophages taken from bleomycin treated rats. Biochem Biophys Res Commun (1992) 0.75
Synthesis and antitumor activity of a series of (aminoethylpyrrolidine) platinum complexes. Cancer Chemother Pharmacol (1989) 0.75
The prevention of cyclophosphamide-induced cystitis in mice by disulfiram. Res Commun Chem Pathol Pharmacol (1982) 0.75
Interleukin-2 and aging: decreased interleukin-2 production in healthy older people does not correlate with reduced helper cell numbers or antibody response to influenza vaccine and is not corrected in vitro by thymosin alpha 1. Immunopharmacology (1985) 0.75
Vinblastine pharmacokinetics measured by a sensitive enzyme-linked immunosorbent assay. Cancer Res (1984) 0.75
Vasoactive intestinal peptide activates both Gs and Gi in lung. Ann N Y Acad Sci (1996) 0.75
Regional fibrosis after intraperitoneal administration of mafosfamide. Invest New Drugs (1986) 0.75
The effect of disulfiram on cyclophosphamide-mediated myeloid toxicity. Cancer Chemother Pharmacol (1986) 0.75
Enhanced Ia expression by alveolar macrophages following intratracheal administration of bleomycin to rats. Immunol Invest (1992) 0.75
Water-soluble N-substituted iminodiacetato(1,2-diaminocyclohexane)-platinum(II) complexes as potential antitumor agents. Cancer Res (1986) 0.75
Toxicity of aziridinylbenzoquinone administered Iv to beagle dogs. Cancer Treat Rep (1982) 0.75
Reduction of acute adriamycin toxicity in mice treated with adenosine. Eur J Cancer Clin Oncol (1983) 0.75
Fibrogenic structure-activity study of the bleomycin molecule. Toxicol Appl Pharmacol (1983) 0.75
Increased systemic, but not regional, neopterin production following intraperitoneal administration of interleukin-2 and lack of effect of pterins upon the lymphokine-activated killer cell phenomenon. J Immunother Emphasis Tumor Immunol (1994) 0.75
Chromosome assignments of the human TNF p55 and p75 receptor genes. J Exp Zool (1992) 0.75
Synthesis and antitumor activity of new platinum complexes. J Med Chem (1982) 0.75
Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice. Invest New Drugs (1984) 0.75
Inheritance of tolerance susceptibility to human gamma-globulin in congenic mice. J Immunol (1979) 0.75
Combination of dihydroxyanthraquinone and radiation on L1210 murine leukemia. Cancer Clin Trials (1981) 0.75
Functional relationships of Lyt-2 and Lyt-3 expression and T-cell cytotoxicity: a new model system. Adv Exp Med Biol (1985) 0.75
A non-characteristic response of L1210 cells to lovastatin. Biochem Biophys Res Commun (1994) 0.75